Skip to content

Prevention and treatment of complications associated with fluid extravasation during shoulder arthroscopy: a randomized controlled double-blind trial

Study on the clinical pathway of anesthesia for shoulder arthroscopy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041236
Enrollment
Unknown
Registered
2020-12-22
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications associated with fluid extravasation during shoulder arthroscopy

Interventions

Sponsors

Sichuan Provincial Orthopedic Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for arthroscopic shoulder surgery; 2. Patients aged 18-60 years, ASA grade I-II, regardless of gender; 3. Patients with 18kg / m2 <= BMI <= 30kg / m2; 4. Patients with normal cognitive function; 5. Those patients who fully understand the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with neck and chest anatomical structure variation or change; 2. Patients who are allergic to the components or components of thiazide diuretics, methylprednisolone, ulinastatin and ropivacaine that may be used in the study; 4. Patients with uncontrolled hypertension and diabetes mellitus (systolic blood pressure >= 160mmhg, or diastolic blood pressure >= 100mmhg, blood glucose >= 15mmol / L); 5. Patients with sleep apnea syndrome and epilepsy before operation; 6. Pregnant or breast-feeding patients with previous history of abuse of psychotropic drugs and narcotic drugs; 7. Patients unable to receive brachial plexus block (skin infection, brachial plexus injury); 8. Patients with severe liver and kidney diseases, pulmonary hypertension, heart failure (NYHA > II), coronary heart disease, myocardial infarction or shunt heart disease; 9. Patients with abnormal coagulation function; 10. Patients who are not suitable to participate in the clinical trial.

Design outcomes

Primary

MeasureTime frame
Edema in adjacent soft tissue;

Countries

China

Contacts

Public ContactLi Su

Sichuan Provincial Orthopedic Hospital

635041501@qq.com+86 13438456433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026